Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA

Fortunato Morabito, Massimo Gentile, Stefania Ciolli, Maria T. Petrucci, Sara Galimberti, Giuseppe Mele, Antonio F. Casulli, Donato Mannina, Eugenio Piro, Graziella Pinotti, Salvatore Palmieri, Lucio Catalano, Vincenzo Callea, Massimo Offidani, Pellegrino Musto, Sara Bringhen, Luca Baldini, Patrizia Tosi, Francesco Di Raimondo, Mario BoccadoroAntonio Palumbo, Michele Cavo

Research output: Contribution to journalArticle

Abstract

Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Bortezomib has been shown to be highly active in MM patients with RI. We designed this retrospective analysis to investigate the safety and efficacy of bortezomib-based therapy in 117 MM patients with RI, 14 cases required dialysis. A total of 603 cycles of bortezomib were administered (median number, five cycles/patient). Ten patients required early discontinuation of bortezomib because of WHO grade IV toxicity. The rate of bortezomib discontinuation in cases with severe, moderate and mild RI was 11%, 5% and 0%, respectively (P = NS). Overall, 91 episodes of WHO grade III/IV toxicity were observed. At least a partial response was documented in 83/113 evaluable patients (73%), including complete response (19%) and near complete response (8%). The overall response rate was similar across RI subgroups. Reversal of RI was documented in 41% of patients after a median of 2.3 months (range 0.4-7.9). In three of 14 patients on dialysis, renal replacement therapy was discontinued after 1, 1 and 4 months. The 2-yr estimate of response duration and overall survival was 70% and 51%, respectively. In conclusion, bortezomib-based regimens are safe and effective and should be considered as appropriate treatment options for MM patients with any degree of RI.

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalEuropean Journal of Haematology
Volume84
Issue number3
DOIs
Publication statusPublished - Mar 2010

    Fingerprint

Keywords

  • Bortezomib
  • Multiple myeloma
  • Renal impairment

ASJC Scopus subject areas

  • Hematology

Cite this

Morabito, F., Gentile, M., Ciolli, S., Petrucci, M. T., Galimberti, S., Mele, G., Casulli, A. F., Mannina, D., Piro, E., Pinotti, G., Palmieri, S., Catalano, L., Callea, V., Offidani, M., Musto, P., Bringhen, S., Baldini, L., Tosi, P., Di Raimondo, F., ... Cavo, M. (2010). Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. European Journal of Haematology, 84(3), 223-228. https://doi.org/10.1111/j.1600-0609.2009.01385.x